홈 › 급성 골수성 백혈병 › 오클라호마 › Oklahoma City
OK Oklahoma City의 급성 골수성 백혈병 임상 시험
급성 골수성 백혈병 관련 연구 14개가 Oklahoma City 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
피험자 모집 중2상
- University of Oklahoma Health Sciences Center, Oklahoma City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
피험자 모집 중관찰 연구건강한 지원자 환영
- Mercy Hospital Oklahoma City, Oklahoma City
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
피험자 모집 중2상
- University of Oklahoma Health Sciences Center, Oklahoma City
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
피험자 모집 중2상
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
피험자 모집 중2상
- University of Oklahoma Health Sciences Center, Oklahoma City
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
피험자 모집 중2상
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
피험자 모집 중3상
- University of Oklahoma Health Sciences Center, Oklahoma City
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
피험자 모집 중1/2상
- University of Oklahoma Health Sciences Center, Oklahoma City
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
피험자 모집 중1상
- University of Oklahoma Health Sciences Center, Oklahoma City
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
피험자 모집 중1상
- OU Health Stephenson Cancer Center, Oklahoma City
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
피험자 모집 중관찰 연구
- University of Oklahoma Health Science Center, Oklahoma City
Pilot Imaging Study of Leukemia
피험자 모집 중1상
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
피험자 모집 중1상
- OU Health Stephenson Cancer Center, Oklahoma City
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
피험자 모집 중2상
- University of Oklahoma Health Sciences Center, Oklahoma City
다른 도시의 급성 골수성 백혈병 시험
- Houston, TX연구 85개
- New York City, NY연구 51개
- Boston, MA연구 44개
- Seattle, WA연구 41개
- Baldwin Park, CA연구 40개
- Columbus, OH연구 35개
- Philadelphia, PA연구 34개
- Durham, NC연구 33개
- Atlanta, GA연구 31개
- Tampa, FL연구 29개
- Chicago, IL연구 26개
- Portland, OR연구 25개
Oklahoma City의 다른 연구
- 비소세포폐암연구 28개
- 난소암연구 28개
- 자궁내막암연구 25개
- 대장직장암연구 22개
- 전립선암연구 21개
- 폐암연구 19개
- 유방암연구 17개
- 전이성 암연구 16개
- 암 (전체)연구 14개
- 두경부 편평세포암연구 13개
- 방광암연구 11개
- 췌장암연구 11개
ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.